Literature DB >> 11207221

Neonatal meningitis in England and Wales: 10 years on.

D E Holt1, S Halket, J de Louvois, D Harvey.   

Abstract

OBJECTIVES: To determine the incidence of neonatal meningitis in England and Wales.
DESIGN: A national postal survey using the British Paediatric Surveillance Unit (BPSU) card scheme supplemented by information from other sources.
SETTING: England and Wales 1996-1997.
SUBJECTS: A total of 274 babies less than 28 days of age who were treated for meningitis.
RESULTS: The incidence of neonatal meningitis in England and Wales has not changed since our previous study in 1985-1987. However, the acute phase mortality has fallen from 19.8% in 1985-1987 to 6.6% in this study. Group B streptococci (42%) and Escherichia coli (16%) remain the most common infecting microorganisms. Eight of 69 (12%) babies with group B streptococci and 4/26 (15%) with E coli died. Antibiotic regimens based on the third generation cephalosporins, notably cefotaxime, were most commonly used (84%). The BPSU scheme identified 72% of cases during the study period. Most cases of viral meningitis were not reported through the BPSU. Less than a third of samples from aseptic meningitis were examined for viruses; 56% of these were positive.
CONCLUSIONS: Although the incidence of neonatal meningitis remains unchanged, mortality from this infection has fallen significantly. If this improvement is maintained as reflected in the level of sequelae at 5 years of age, then the fear surrounding meningitis during the neonatal period will have been dramatically reduced.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11207221      PMCID: PMC1721232          DOI: 10.1136/fn.84.2.f85

Source DB:  PubMed          Journal:  Arch Dis Child Fetal Neonatal Ed        ISSN: 1359-2998            Impact factor:   5.747


  10 in total

Review 1.  Bacterial meningitis in the newborn: a prospective study of mortality and morbidity.

Authors:  D Harvey; D E Holt; H Bedford
Journal:  Semin Perinatol       Date:  1999-06       Impact factor: 3.300

2.  Infantile meningitis in England and Wales: a two year study.

Authors:  J de Louvois; J Blackbourn; R Hurley; D Harvey
Journal:  Arch Dis Child       Date:  1991-05       Impact factor: 3.791

Review 3.  Management of bacterial meningitis: 1998.

Authors:  L Wubbel; G H McCracken
Journal:  Pediatr Rev       Date:  1998-03

4.  Potential cost savings through rapid diagnosis of enteroviral meningitis.

Authors:  G S Marshall; M A Hauck; G Buck; G P Rabalais
Journal:  Pediatr Infect Dis J       Date:  1997-11       Impact factor: 2.129

5.  Validation of the reporting bases of the orthopaedic and paediatric surveillance schemes.

Authors:  S Godward; C Dezateux
Journal:  Arch Dis Child       Date:  1996-09       Impact factor: 3.791

6.  The importance of the virology laboratory in the diagnosis and management of viral meningitis.

Authors:  S Wildin; T Chonmaitree
Journal:  Am J Dis Child       Date:  1987-04

7.  The British Paediatric Surveillance Unit.

Authors:  S M Hall; M Glickman
Journal:  Arch Dis Child       Date:  1988-03       Impact factor: 3.791

8.  Controversies in the management of childhood meningitis.

Authors:  H Peltola
Journal:  J Med Microbiol       Date:  1997-11       Impact factor: 2.472

9.  Epidemiology of bacterial meningitis.

Authors:  H M Fortnum; A C Davis
Journal:  Arch Dis Child       Date:  1993-06       Impact factor: 3.791

Review 10.  Acute bacterial meningitis in the newborn.

Authors:  J de Louvois
Journal:  J Antimicrob Chemother       Date:  1994-08       Impact factor: 5.790

  10 in total
  32 in total

1.  Long term outcome of neonatal meningitis.

Authors:  J P Stevens; M Eames; A Kent; S Halket; D Holt; D Harvey
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2003-05       Impact factor: 5.747

2.  Extracellular loops of the Eschericia coli outer membrane protein A contribute to the pathogenesis of meningitis.

Authors:  Ravi Maruvada; Kwang Sik Kim
Journal:  J Infect Dis       Date:  2011-01-01       Impact factor: 5.226

3.  Effect of meningitis in infancy on school-leaving examination results.

Authors:  John de Louvois; Sue Halket; David Harvey
Journal:  Arch Dis Child       Date:  2007-03-22       Impact factor: 3.791

4.  Neonatal meningitis in England and Wales: sequelae at 5 years of age.

Authors:  John de Louvois; Susan Halket; David Harvey
Journal:  Eur J Pediatr       Date:  2005-09-01       Impact factor: 3.183

5.  Molecular characterization and prophage DNA contents of Streptococcus agalactiae strains isolated from adult skin and osteoarticular infections.

Authors:  Mazen Salloum; Nathalie van der Mee-Marquet; Anne-Sophie Domelier; Laurence Arnault; Roland Quentin
Journal:  J Clin Microbiol       Date:  2010-02-24       Impact factor: 5.948

6.  Host cytosolic phospholipase A₂α contributes to group B Streptococcus penetration of the blood-brain barrier.

Authors:  Ravi Maruvada; Longkun Zhu; Donna Pearce; Adam Sapirstein; Kwang Sik Kim
Journal:  Infect Immun       Date:  2011-08-08       Impact factor: 3.441

7.  IbeA and OmpA of Escherichia coli K1 exploit Rac1 activation for invasion of human brain microvascular endothelial cells.

Authors:  Ravi Maruvada; Kwang Sik Kim
Journal:  Infect Immun       Date:  2012-03-26       Impact factor: 3.441

Review 8.  Clinical microbiology of bacterial and fungal sepsis in very-low-birth-weight infants.

Authors:  David Kaufman; Karen D Fairchild
Journal:  Clin Microbiol Rev       Date:  2004-07       Impact factor: 26.132

9.  Hyperinvasive neonatal group B streptococcus has arisen from a bovine ancestor.

Authors:  Naiel Bisharat; Derrick W Crook; James Leigh; Rosalind M Harding; Phil N Ward; Tracey J Coffey; Martin C Maiden; Tim Peto; Nicola Jones
Journal:  J Clin Microbiol       Date:  2004-05       Impact factor: 5.948

10.  Brain magnetic resonance imaging of infants with bacterial meningitis.

Authors:  Carlos R Oliveira; Michael C Morriss; John G Mistrot; Joseph B Cantey; Christopher D Doern; Pablo J Sánchez
Journal:  J Pediatr       Date:  2014-04-13       Impact factor: 4.406

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.